| Curable neoplasms and the ethics of clinical trials |
| LH Einhorn |
|
JCO Apr 1 1993: 593–595.
[PDF]
|
 |
| Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer |
| GL Andriole |
|
JCO Apr 1 1993: 596–597.
[PDF]
|
|
|
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study |
| |
DF Bajorin, MF Sarosdy, DG Pfister, M Mazumdar, RJ Motzer, HI Scher, NL Geller, WR Fair, H Herr, and P Sogani |
| |
JCO Apr 1 1993: 598–606.
[Abstract]
[PDF]
|
|
|
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer |
| |
WK Kelly, HI Scher, M Mazumdar, V Vlamis, M Schwartz, and SD Fossa |
| |
JCO Apr 1 1993: 607–615.
[Abstract]
[PDF]
|
|
|
Prognostic factors in medulloblastoma, including DNA ploidy |
| |
C Zerbini, RD Gelber, D Weinberg, SE Sallan, P Barnes, W Kupsky, RM Scott, and NJ Tarbell |
| |
JCO Apr 1 1993: 616–622.
[Abstract]
[PDF]
|
|
|
Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma |
| |
LA Campbell, RC Seeger, RE Harris, JG Villablanca, and KK Matthay |
| |
JCO Apr 1 1993: 623–629.
[Abstract]
[PDF]
|
|
|
Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d'Oncologie Pediatrique |
| |
V Meresse, G Vassal, J Michon, C De Cervens, B Courbon, H Rubie, Y Perel, J Landman, P Chastagnier, and C De Valck |
| |
JCO Apr 1 1993: 630–637.
[Abstract]
[PDF]
|
|
|
Role of computed tomography in the staging of primary melanoma |
| |
AC Buzaid, AB Sandler, S Mani, AM Curtis, WJ Poo, JL Bolognia, and S Ariyan |
| |
JCO Apr 1 1993: 638–643.
[Abstract]
[PDF]
|
|
|
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy |
| |
BW Dana, S Dahlberg, BN Nathwani, E Chase, C Coltman, TP Miller, and RI Fisher |
| |
JCO Apr 1 1993: 644–651.
[Abstract]
[PDF]
|
|
|
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2 |
| |
BD Curti, DL Longo, AC Ochoa, KC Conlon, JW Smith, 2d, WG Alvord, SP Creekmore, RG Fenton, BL Gause, and J Holmlund |
| |
JCO Apr 1 1993: 652–660.
[Abstract]
[PDF]
|
|
|
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma |
| |
MB Atkins, J Sparano, RI Fisher, GR Weiss, KA Margolin, KI Fink, L Rubinstein, A Louie, JW Mier, and R Gucalp |
| |
JCO Apr 1 1993: 661–670.
[Abstract]
[PDF]
|
|
|
2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies |
| |
A Saven, H Kawasaki, CJ Carrera, T Waltz, B Copeland, J Zyroff, M Kosty, DA Carson, E Beutler, and LD Piro |
| |
JCO Apr 1 1993: 671–678.
[Abstract]
[PDF]
|
|
|
High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count |
| |
G Juliusson and J Liliemark |
| |
JCO Apr 1 1993: 679–689.
[Abstract]
[PDF]
|
|
|
Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia |
| |
MS Tallman, D Hakimian, JM Shaw, GS Lissner, EJ Russell, and D Variakojis |
| |
JCO Apr 1 1993: 690–697.
[Abstract]
[PDF]
|
|
|
Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease |
| |
PJ Bierman, JM Vose, PK Leichner, SM Quadri, JO Armitage, JL Klein, RA Abrams, KA Dicke, and HM Vriesendorp |
| |
JCO Apr 1 1993: 698–703.
[Abstract]
[PDF]
|
|
|
High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant |
| |
M Crump, AM Smith, J Brandwein, F Couture, H Sherret, DM Sutton, JG Scott, J McCrae, C Murray, and D Pantalony |
| |
JCO Apr 1 1993: 704–711.
[Abstract]
[PDF]
|
|
|
MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group |
| |
PG Gobbi, C Pieresca, M Federico, N Di Renzo, F Narni, E Iannitto, G Grignani, L Cavanna, P Avanzini, and G Partesotti |
| |
JCO Apr 1 1993: 712–719.
[Abstract]
[PDF]
|
|
|
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non- Hodgkin's lymphomas |
| |
C Tondini, M Zanini, F Lombardi, C Bengala, A Rocca, R Giardini, R Buzzoni, P Valagussa, and G Bonadonna |
| |
JCO Apr 1 1993: 720–725.
[Abstract]
[PDF]
|
|
|
Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms |
| |
ML Grossbard, JM Lambert, VS Goldmacher, NL Spector, J Kinsella, L Eliseo, F Coral, JA Taylor, WA Blattler, and CL Epstein |
| |
JCO Apr 1 1993: 726–737.
[Abstract]
[PDF]
|
|
|
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250 |
| |
E Oosterwijk, NH Bander, CR Divgi, S Welt, JC Wakka, RD Finn, EA Carswell, SM Larson, SO Warnaar, and GJ Fleuren |
| |
JCO Apr 1 1993: 738–750.
[Abstract]
[PDF]
|
|
|
Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer |
| |
LL Danhauser, JH Freimann, Jr, TL Gilchrist, JU Gutterman, CY Hunter, AC Yeomans, and AB Markowitz |
| |
JCO Apr 1 1993: 751–761.
[Abstract]
[PDF]
|
|
|
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia |
| |
CL Loprinzi, JC Michalak, DJ Schaid, JA Mailliard, LM Athmann, RM Goldberg, LK Tschetter, AK Hatfield, and RF Morton |
| |
JCO Apr 1 1993: 762–767.
[Abstract]
[PDF]
|
|
|
Postchemotherapy rheumatism |
| |
CL Loprinzi, J Duffy, and JN Ingle |
| |
JCO Apr 1 1993: 768–770.
[Abstract]
[PDF]
|
|
|
The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women |
| |
TJ Smith and BE Hillner |
| |
JCO Apr 1 1993: 771–776.
[Abstract]
[PDF]
|
|
|
Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life- expectancy outcomes |
| |
CE Desch, BE Hillner, TJ Smith, and SM Retchin |
| |
JCO Apr 1 1993: 777–782.
[Abstract]
[PDF]
|
|
|
Characteristics of women at risk for psychosocial distress in the year after breast cancer |
| |
CA Schag, PA Ganz, ML Polinsky, C Fred, K Hirji, and L Petersen |
| |
JCO Apr 1 1993: 783–793.
[Abstract]
[PDF]
|
|
|
Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials |
| |
EL Korn and R Simon |
| |
JCO Apr 1 1993: 794–801.
[Abstract]
[PDF]
|
|
|
Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma |
| |
RA Shivdasani, JL Hess, AT Skarin, and GS Pinkus |
| |
JCO Apr 1 1993: 802–111.
[Abstract]
[PDF]
|
|
| Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma |
| CH Weaver, F Appelbaum, FB Petersen, and CD Buckner |
|
JCO Apr 1 1993: 812–813.
[PDF]
|
|
